Faculty

Carine Peeters

Prof Carine Peeters
Professor of Strategy and International Business at Vlerick Business School

Carine is Vlerick’s expert in the field of international business & strategy, with a particular interest in emerging markets as well as service sourcing strategies and delivery models. A firm believer in innovation, Carine is always eager to share and co-create knowledge with participants and to try out new methods to enrich the learning experience and make it stick.
Wouter De Maeseneire

Prof Wouter De Maeseneire 
Professor of Corporate Finance at Vlerick Business School

A passionate and experienced teacher, Wouter thoroughly enjoys explaining financial management principles by linking finance to business models and corporate strategies. His classes are often centred around self-developed cases that discuss the ABInbev deal, Walmart’s financial statements, Dell’s working capital management, Facebook’s IPO debacle, and Apple’s cash position.
Filip Roodhooft

Prof Filip Roodhooft
Professor of Accounting at Vlerick Business School

Filip’s teaching is focused primarily on the finance function as a business partner for an organisation. He also shows non-financial managers the relevance of accounting information for decision-making and strategy execution.
Katleen De Stobbeleir

Prof Katleen De Stobbeleir
Professor of Leadership & Coaching at Vlerick Business School

Passionate about developing leadership at all organisational levels, Katleen De Stobbeleir is and one of the leading faculty members in leadership, management skills and feedback skills. Furthermore, she is an executive coach and a certified consultant in Investors in People and Great Place to Work.

Peter De Prins

Prof Peter De Prins
Professor of Change & Leadership at Vlerick Business School

Peter is a passionate teacher and executive coach, delivering inspiring experiences and taking you on a journey of impactful insights that ultimately result in an increase of your personal and professional performance. Peter teaches change management, leadership and and focuses on the practical use of theoretical and academic models, making use of group-participation and collaborative learning.
Brecht Cardoen

Prof Brecht Cardoen
Associate Professor at Vlerick Business School

Brecht heads MINOZ, a research network focusing on hospital operations management and contributes to a wide variety of research projects. His research interests are directed to optimisation and decision sciences in services, with a particular interest in healthcare services.

Marc Noppen

Prof Marc Noppen
CEO at UZ Brussel

Paul Gemmel

Prof Paul Gemmel
Professor at Ghent University

Staf Van Herck

Prof Staf Van Herck
Chairman of the Board at Jan Yperman Ziekenhuis Ieper

Katrien Kesteloot

Prof Katrien Kesteloot
Financial director at UZ Leuven

Drive real change in your organisation

A learning experience with real impact on your operations? A management programme tailored to the specific needs of your business? Contact us and discover how we can design and deliver customised programmes for your team that add genuine value to your organisation.

Need help?

Contact our Programme Advisor
Programme Advisor
Tel + 32 9 210 98 84
programmeadvisor@vlerick.com
Find the programme most relevant for you!

Our programme finder allows you to find the management programme that best fits your needs.

Find a Programme

Meet Us

Info Sessions & Open Days
20 Apr
Drop In on our Leuven Campus
Category: General Info Sessions

09 May
Drop In on our Ghent Campus
Category: General Info Sessions

02 Jun
Drop In on our Brussels Campus
Category: General Info Sessions

Our approach to learning

It’s all about you and your company’s challenges at Vlerick Business School. Discover our unique approach to learning!

Vlerick expertise in Healthcare Management

  1. Pharma and data as gospel

    Developing drugs is a time-consuming process. In order to speed it up, the Belgian biopharmaceuticals producer UCB has decided to switch to a data-driven organisation. It was necessary to ‘convert’ the entire company to achieve this, says CIO Herman De Prins.
  2. Innovative cancer treatments: how much are we willing to pay?

    One man in three and one woman in four will develop cancer before their 75th birthday. In Belgium, cancer is the second major cause of disease burden after cardiovascular diseases and it is unlikely this will change in the foreseeable future. Increasingly better but more expensive cancer therapies are becoming available. Needless to say, in these times of austerity, the public budget for cancer treatment is under pressure. How can we ensure all patients continue to have access to these expensive but potentially life-saving medicines at a price society can afford, while at the same time encouraging pharmaceutical companies to innovate?
All articles